Compugen Reports Q3 2026 Financial Results and Clinical Pipeline Updates
Compugen Ltd. (CGEN) reported third-quarter 2026 revenue of $3.8 million, driven by milestone payments from its license agreement with Gilead. The company narrowed its net loss to $5.8 million, an improvement over the $7 million loss recorded in the same period last year. Compugen maintains a strong liquidity position with $117.5 million in cash and equivalents, providing a projected runway into 2029. On the clinical front, the company completed patient enrollment for its MAIA-Ovarian trial evaluating COM701, with high-level data expected by Q1 2027. Additionally, Compugen's partnership with AstraZeneca continues to progress with rilvegostomig undergoing 12 ongoing Phase 3 studies. The company remains positioned to receive significant future milestone payments from both Gilead and AstraZeneca as its pipeline advances through regulatory stages.
Topics: cash runway clinical trial update earnings report net loss revenue